secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001437749-25-024849
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025
------------------------------------------------------------------------------

- Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).
- Cash and marketable securities $175.5M as of June 30, 2025; cash runway through 2027.
- PIPE-307 Phase 2 VISTA (RRMS) top line data expected Q4 2025; PIPE-791 PET data Q3 2025.
- Global PIPE-791 Phase 2 IPF trial initiation planned Q4 2025; PrMS and CTX-343 postponed.
- Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/0001437749-25-024849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ctnm20250616_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer